Valuation: ME Therapeutics Holdings Inc.

Market Cap 88.35M 62.96M 55.13M 50.92M 46.89M 6.07B 90.39M 608M 239M 2.97B 237M 231M 10.24B P/E 2024
-51.7x
P/E 2025 -93.2x
Enterprise Value 87.01M 62.01M 54.3M 50.15M 46.18M 5.97B 89.03M 598M 235M 2.93B 233M 228M 10.08B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.99%
Yield 2024 *
-
Yield 2025 -
1 day+47.74%
1 week+47.74%
Current month+47.74%
1 month+47.74%
3 months+17.60%
6 months-2.00%
Current year-26.50%
1 week 1.9
Extreme 1.9
2.94
1 month 0.79
Extreme 0.79
2.94
Current year 0.79
Extreme 0.79
3.8
1 year 0.79
Extreme 0.79
8
3 years 0.05
Extreme 0.05
11
5 years 0.05
Extreme 0.05
11
10 years 0.05
Extreme 0.05
11
Manager TitleAgeSince
Chief Executive Officer 46 09/03/2023
Director of Finance/CFO 44 09/03/2023
Corporate Officer/Principal - 25/10/2024
Director TitleAgeSince
Director/Board Member 60 09/03/2023
Director/Board Member 46 09/03/2023
Director/Board Member 59 09/03/2023
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Buy 200 0.0007%
24/02/26 Buy

Company Secretary

100 0.0003%
24/02/26 Buy

Company Secretary

100 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+47.74%+47.74%-41.20% - 63.06M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +4.82%+0.02%+54.07%+98.43% 24.37B
Weighted average by Cap. -0.04%-0.18%+79.41%+123.32%

Financials

2024 2025
Net sales - -
Net income -1.29M -923K -808K -746K -687K -88.89M -1.32M -8.9M -3.5M -43.58M -3.47M -3.39M -150M -1.19M -850K -745K -688K -633K -81.92M -1.22M -8.21M -3.22M -40.16M -3.2M -3.13M -138M
Net Debt -1.5M -1.07M -934K -863K -794K -103M -1.53M -10.29M -4.04M -50.38M -4.01M -3.92M -173M -1.33M -949K -831K -767K -707K -91.4M -1.36M -9.15M -3.6M -44.81M -3.57M -3.49M -154M
Logo ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immune oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The Company has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. METX Stock